Poultry virus vaccines that are liquid stable

Abstract

The present invention is drawn to liquid stable poultry vaccines that comprise a live avian virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines.

1 . A liquid stable vaccine that comprises a live poultry virus, a 5-40% (w/v) sugar alcohol, and 0.15 to 0.75 M of an amino acid selected from the group consisting of arginine, glutamic acid, and glycine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0; wherein the live poultry virus is selected from the group consisting of an attenuated virus, a recombinant poultry viral vector, and a recombinant viral vector of an attenuated poultry virus; and wherein the recombinant poultry viral vector or the recombinant viral vector of an attenuated poultry virus can further encode a heterologous antigen. 
     
     
         2 . The liquid stable vaccine of  claim 1  wherein the sugar alcohol is sorbitol. 
     
     
         3 . The liquid stable vaccine of  claim 2  wherein the amino acid is arginine. 
     
     
         4 . The liquid stable vaccine of  claim 3 , wherein the live poultry virus is selected from the group consisting of a Infectious Bursal Disease Virus (IBDV), Newcastle Disease Virus (NDV), Marek's disease virus (MDV), avian metapneumovirus (aMPV), Herpesvirus of Turkey (HVT), and any combination thereof. 
     
     
         5 . The liquid stable vaccine of  claim 1  further comprising a sugar additive that is a non-sugar alcohol, wherein the total amount of the sugar alcohol and the non-sugar alcohol in the liquid stable vaccine is 15-40% (w/v). 
     
     
         6 . The liquid stable vaccine of  claim 5  wherein the non-sugar alcohol is selected from the group consisting of sucrose and trehalose. 
     
     
         7 . The liquid stable vaccine of  claim 1  that further comprises a buffer. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . The liquid stable vaccine of  claim 4 , wherein the live attenuated virus is an NDV. 
     
     
         11 . (canceled) 
     
     
         12 . The liquid stable vaccine of  claim 10  that further comprises a live attenuated IBDV. 
     
     
         13 . The liquid stable vaccine of  claim 4 , wherein the live attenuated virus is an IBDV. 
     
     
         14 . The liquid stable vaccine of  claim 12  that further comprises a live attenuated MDV or a recombinant attenuated MDV vector that encodes a heterologous antigen. 
     
     
         15 . The liquid stable vaccine of  claim 12  that further comprises a live HVT, or a recombinant HVT vector that encodes a heterologous antigen. 
     
     
         16 . The liquid stable vaccine of  claim 15  that further comprises a live attenuated aMPV. 
     
     
         17 . The liquid stable vaccine of  claim 4  that further comprises a killed poultry virus. 
     
     
         18 . The liquid stable vaccine of  claim 4  that further comprises a bacterium selected from the group consisting of a live attenuated  Pasteurella multocida , a live attenuated  Salmonella enteritidis , a live attenuated  Avibacterium paragallinarum , a live attenuated  Mycoplasma gallisepticum , a live  Clostridium perfringens , a killed  Pasteurella multocida , a killed  Salmonella enteritidis , a killed  Avibacterium paragallinarum , a killed  Mycoplasma gallisepticum , an inactivated toxoid of  Clostridium perfringens , and any combination thereof. 
     
     
         19 - 21  (canceled) 
     
     
         22 . The method of  claim 23 , wherein said administering is performed by subcutaneous injection. 
     
     
         23 . A method of vaccinating an avian against a poultry virus comprising administering to the avian the liquid stable vaccine of  claim 1 . 
     
     
         24 . The method of  claim 23 , wherein said administering is performed by spray or feeding. 
     
     
         25 . A method of making a liquid stable vaccine that comprises combining a therapeutically effective amount of a live attenuated poultry virus with a 5-40% (w/v) sugar alcohol, and 0.15 to 0.75 M arginine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0. 
     
     
         26 - 50 . (canceled)